Clopidogrel, aspirin and rivaroxaban after a medical procedure used to widen narrowed or blocked arteries using a balloon or stent

Submission date 28/06/2024	Recruitment status Recruiting	[X] Prospectively registered
		[_] Protocol
Registration date	Overall study status	Statistical analysis plan
22/08/2024	Ongoing	[_] Results
Last Edited	Condition category	[_] Individual participant data
22/01/2025	Circulatory System	[X] Record updated in last year

Plain English summary of protocol

Background and study aims

Blocked leg arteries, often caused by diabetes or smoking, are increasingly common and can result in potentially severe consequences like amputation or even death if left untreated. In the UK, between 16,500 and 30,000 people die and 3,500 face amputations due to heavily blocked leg arteries annually. Each year, over 4,000 angioplasty medical procedures are conducted in the UK to widen narrowed or blocked arteries using a balloon or stent. After an angioplasty, patients typically receive medications known as "blood thinners" to prevent blood clots and lower the chance of needing an amputation. Despite the widespread use of various tablet combinations by vascular surgeons in the UK, the optimal blood thinners for effectiveness and safety remain unknown.

This research will compare three commonly used blood thinners after angioplasty: Clopidogrel alone, Aspirin and Clopidogrel, and Aspirin and Rivaroxaban. The research will be 'randomised', meaning that patients will be randomly chosen by a computer to receive one of the three treatments, ensuring equal chances for each. Everything else will be the same.

The research aims to determine the optimal blood thinners for preventing complications of blocked arteries after angioplasty without causing too much bleeding. The research will also assess how much value these treatments provide in terms of their cost for the National Health Service (NHS). The results are expected to help improve the care of many patients needing angioplasty in the future.

Who can participate?

This research will involve roughly 20 vascular units in the UK, with 1,239 participants undergoing angioplasty in the lower leg due to blocked arteries.

What does the study involve?

Within 10 days of angioplasty, participants will start taking the assigned blood thinners for up to three years. We will ask participants about their quality of life and will be monitored for health problems such as further blockages, amputations, heart attacks, strokes and serious bleeding.

What are the possible benefits and risks of participating? Benefits:

By participating in this trial, you will be helping us to answer questions about the optimal bloodthinners after angioplasty in the lower leg that may result in better care for patients needing this in the future. We know patients who are enrolled in randomised trials tend to do better medically than those who are not, probably because they have more points of contact with the hospital.

Risks:

The major burden on participants is the time taken to complete pain and quality of life questionnaires at baseline and 2, 6 and 12 months and possibly at 24 and 36 months after their procedure. While there are potential risks to taking the medicinal products, the risk is no higher than the risk of standard medical care. These medicines will be used within the licensed range of indications, dosage and form, and are all and are all currently used in UK clinical practice to all patients after endovascular intervention to reduce the risk of subsequent ischaemic events such as acute limb ischemia or myocardial infarction outside of the trial. The known and most commonly anticipated safety issue is bleeding risk. To minimise risks, patients at risk of increased bleeding will be excluded. E.g. patients with pre-existing indication for dual antiplatelet therapy or anticoagulant (atrial fibrillation and inherited and acquired bleeding disorders), open bypass as part of hybrid procedure, , active malignancy or any other non-vascular condition associated with a life expectancy of less than 36 months, embolic arterial disease, non-atherosclerotic Peripheral Arterial Disease (PAD), renal failure with creatinine clearance <15 ml/minute.

Some patients have arterial disease in more than one territory (e.g. peripheral arterial disease and coronary artery disease; polyvascular disease) and are known to be at higher risk of both ischaemic and bleeding events. The bleeding risk of some patients with polyvascular disease will exclude them from CLARITY PAD.

Patients taking anticoagulants are to be carefully observed for signs of bleeding. Major bleeding is our primary safety outcome and other bleeding outcomes will be followed up as secondary outcome measures. The anticipated safety issues will be addressed within normal clinical practice.

Patients will be monitored for signs of bleeding and treatment should be stopped if severe bleeding occurs. In addition to restrictive eligibility criteria, other risk mitigation strategies include trial oversight from the Trial Management Group (TMG), Independent Data Monitoring Committee (IDMC) and Trial Steering Committee (TSC).

Where is the study run from? Cardiff University (UK)

When is the study starting and how long is it expected to run for? June 2024 to December 2028

Who is funding the study? National Institute for Health and Care Research (NIHR) (UK).

Who is the main contact? Clarity-Trial@cardiff.ac.uk

Study website https://www.claritypadtrial.co.uk

Contact information

Type(s) Scientific

Contact name Dr Wakunyambo Maboshe

Contact details Centre for Trials Research, 7th Floor, Neuadd Meirionnydd, Heath Park Cardiff United Kingdom CF14 4YS

+44 29 20687457 maboshew1@cardiff.ac.uk

Type(s) Scientific, Principal Investigator

Contact name Mr Christopher Twine

Contact details Southmead Hospital, Southmead Road, Westbury-on-Trym Bristol United Kingdom BS10 5NB +44 1174 4140826 christopher.twine@bristol.ac.uk

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number 1007268

ClinicalTrials.gov number Nil known

Secondary identifying numbers R&D 5410, IRAS 1007268

Study information

Scientific Title

CLopidogrel, Aspirin and RIvaroxaban after revascularisation with angioplasTY for limbthreatening Peripheral Arterial Disease (CLARITY PAD)

Acronym

CLARITY PAD

Study objectives

Primary objective:

To compare the clinical effectiveness of three commonly used antithrombotic regimens (clopidogrel; aspirin plus clopidogrel; aspirin plus low-dose rivaroxaban) following endovascular intervention for CLTI

Secondary objectives:

1. To evaluate the effect of three commonly used antithrombotic regimens on major adverse limb events, major adverse cardiovascular events, major bleeding, minor bleeding, primary and secondary patency of artery, reintervention, healing of tissue loss, health-related quality of life, resource use and costs.

2. To evaluate the delivery of the CLARITY trial and trial interventions through qualitative process evaluation

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 21/08/2024, Wales REC 5 (Castlebridge 4, 15-19 Cowbridge Rd E, Cardiff, CF11 9AB, United Kingdom; +44 2921 052459; Wales.REC5@Wales.nhs.uk), ref: 24/WA/0211

Study design

Pragmatic adaptive multicentre open-label three-arm individually randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s) Hospital

Study type(s) Safety, Efficacy

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Antithrombotic treatment after percutaneous or hybrid endovascular intervention for chronic limb-threatening ischemia of the lower limbs

Interventions

Oral course (up to 36 months) of one of the following treatments:

1. A 75mg clopidogrel tablet taken once daily

2. Dual antiplatelet therapy with a 75mg aspirin tablet and 75mg clopidogrel tablet, both taken once daily

3. Dual antiplatelet therapy with a 75mg aspirin tablet taken once daily and a 2.5mg rivaroxaban tablet taken twice daily

Participants in all trial arms will be followed up within 2-months of the procedure, at 6 months and annually post-procedure.

Treatment and follow-up duration will range between 1 year and 3 years depending on when the participant joins the trial.

Intervention Type

Drug

Pharmaceutical study type(s)

Pharmacoeconomic, Therapy, Others (A qualitative process evaluation study of 10-20 health professionals and 20-30 patients and a qualitative study within a trial (SWAT) of 10-20 patients and participating clinicians (n=10-20) to understand how to better recruit patients with higher risk of bleeding and often excluded from randomised controlled trials for future research.)

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Aspirin, clopidogrel besilate, rivaroxaban

Primary outcome measure

A composite event-free survival time of:

- 1. Acute limb ischaemia
- 2. Major lower limb amputation
- 3. Myocardial infarction
- 4. Ischaemic stroke
- 5. All-cause mortality

Measured using patient records at 2 months, 6 months, 12 months, 24 months and 36 months

Secondary outcome measures

Measured via case report forms (CRFs) or questionnaires either from patient notes or directly from participants at 2 months, 6 months, 12 months, 24 months and 36 months:

1. Major adverse limb events (MALE) (defined as amputation or major reintervention of the trial limb)

2. Major adverse cardiovascular events (MACE) (defined as recurrent CLTI, amputation affecting contralateral limb, acute coronary syndrome, ischaemic stroke)

3. Bleeding Academic Research Consortium (BARC 2, 3 or 5) and Thrombolysis In Myocardial Infarction (TIMI) defined major bleeding

4. Minor bleeding

- 5. Primary and secondary patency of artery
- 6. Reintervention
- 7. Healing of tissue loss
- 8. Health-related quality of life (VascuQoL and EQ-5D-5L)

9. Cost-effectiveness

10. Qualitative process evaluation

Overall study start date 02/01/2024

Completion date

31/12/2028

Eligibility

Key inclusion criteria

1. Adults (aged 18 years and over) undergoing percutaneous or hybrid endovascular intervention for CLTI of the lower limbs

2. Atherosclerosis as the cause of CLTI

3. Target arteries: infrainguinal (common femoral to pedal) if percutaneous, or iliac to pedal if performed as part of hybrid revascularisation with common femoral endarterectomy

4. Clinicians would use trial antithrombotic combinations in normal clinical practice

- 5. Able to provide informed consent
- 6. First time in the CLARITY trial

Participant type(s)

Patient

Age group

Adult

Lower age limit 18 Years

Sex

Both

Target number of participants

1,239

Key exclusion criteria

1. Open lower-limb bypass as part of hybrid procedure

2. Pre-existing clinical indication for dual antiplatelet therapy or anticoagulant e.g. atrial fibrillation

3. Active malignancy or any other non-vascular condition associated with a life expectancy of less than 36 months

4. Patients undergoing intervention to treat asymptomatic restenosis of a lower-limb bypass graft

5. Embolic arterial disease

6. Renal failure with creatinine clearance <15ml/minute

7. Thrombophilia or any other inherited or acquired bleeding disorders

8. Persons of childbearing potential who have a positive pregnancy test, are breastfeeding or attempting pregnancy

Date of first enrolment

14/01/2025

Date of final enrolment 30/06/2027

Locations

Countries of recruitment England

United Kingdom

Wales

Study participating centre Southmead Hospital Southmead Road Westbury-on-trym Bristol United Kingdom BS10 5NB

Study participating centre University Hospital of Wales Heath Park Cardiff United Kingdom CF14 4XW

Study participating centre St Thomas' Hospital Westminster Bridge Road London United Kingdom SE1 7EH

Study participating centre St Georges University Hospital Blackshaw Road London United Kingdom SW17 0QT

Study participating centre Leeds General Infirmary

Great George Street Leeds United Kingdom LS1 3EX

Study participating centre Hull Royal Infirmary Anlaby Road

Hull United Kingdom HU3 2JZ

Study participating centre St Marys Hospital

St. Marys Hospital Floyd Drive Warrington United Kingdom WA2 8DB

Study participating centre Northern General Hospital

Northern General Hospital NHS Trust C Floor, Huntsmnan Building Herries Road Sheffield United Kingdom S5 7AU

Study participating centre Addenbrookes

Addenbrookes Hospital Hills Road Cambridge United Kingdom CB2 0QQ

Sponsor information

Organisation North Bristol NHS Trust

Sponsor details Level 3, Learning & Research building Southmead Hospital Westbury on Trym Bristol England United Kingdom BS10 5NB

researchsponsor@nbt.nhs.uk

Sponsor type University/education

Website http://www.nbt.nhs.uk/

ROR https://ror.org/036x6gt55

Funder(s)

Funder type Government

Funder Name Health Technology Assessment Programme

Alternative Name(s) NIHR Health Technology Assessment Programme, HTA

Funding Body Type Government organisation

Funding Body Subtype National government

Location United Kingdom

Results and Publications

Publication and dissemination plan

The findings will be presented at medical conferences, published in free to access medical journals, and shared with people who

write peripheral arterial disease (PAD) guidelines and policies. We will share results via the national press, relevant charities and social media.

Intention to publish date

30/06/2029

Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date